David McIntosh Amplifies Archil Jaliashvili’s Call to End Nigeria’s Blood Shortage Crisis
David McIntosh, Founder and Chair of United Plasma Action, shared a post by Archil Jaliashvili on LinkedIn:
”This Nigerian plea echoes across Low and Middle Income Countries world-wide.
Shortages of blood, plasma and plasma-derived medicines are a deadlier global pandemic than Covid.
Please spread the word – none of this is necessary – none of these shortages are unavoidable. They’re not even very hard to correct.
What’s needed, to save the suffering and save the millions of lives currently being lost..??
• Government and Communities commitment
• Willpower and investment
There is nothing unknown or technologically difficult about any of this.
We just need to get on and DO IT.”
Quoting Archil Jaliashvili’s post:
”Nigeria’s Blood Shortage Humanitarian Crisis
And a $16.8 Billion Opportunity to save LIves
Nigeria faces a natioanl emergency: every year, 1.7-1.8 million units of blood are needed, but only ~500,000 units are collected—fulfilling just 27-30 % of demand.
This shortage costs lives – particularly from anemia, postpartum hemorrhage, sepsis, sickle cell complications, trauma, and other emergencies.
– Only 10-15 % of donations come from voluntary, non-remunerated donors.
Most blood comes from family replacement of paid donors,
raising concerns about safety and long-term sustainability.
Think differently:
BHOC – Biological Hemoglobin Oxygen Carrier are a bridge to recovery.
Early case studies show patients recovering even when donor blood was unavailable (Jehovah’s Witness).
BHOC complements traditional healthcare, acting as a metabolic support technology that provides critical oxygen-carrying capacity during blood shortages.
It works in harmony with the body’s natural systems, wich was creating millions of year, offering a life-saving solution when conventional options are limited.
Economic Impact in Nigeria:
• Reducing shortages by 50 % →$ 135M annual savings
– Fewer complications
– Shorter hospital stays
– Reduced emergency procurement costs
Lives Saved = Economic Value:
• ~8,000 lives saved annually → 80,000 over 10 years
• Using human capital valuation (~ $7,000 per life-year)× 30 life years/person: 80,000 × $210,000= $16.8B
Conclusion BHOC:
• Compatible with all blood groups
• Rapidly eliminates anemia
• Acting as an iron supplement, stimulates EPO
• Shelf life + 3 years at room temperature
• No risk of infection, immune reaction
- BHOC – Biological Hemoglobin Oxygen Carrier
- Saving lives and can generating
- ~$16.8 B in economic value for Nigeria.
We invite everybody think differently, join to build an Advisory and Support Network dedicated to advancing critical care, addressing unmet medical needs.”

Stay updated with Hemostasis Today.
-
Jan 22, 2026, 15:36We Must Roll Up Our Sleeves And Help: José Antonio García Erce on Plasma Donation
-
Jan 22, 2026, 15:25Nita Radhakrishnan on Challenges In Congenital Afibrinogenemia
-
Jan 22, 2026, 15:10Jin Q Gives a Summary of 2025’s Most Impactful Cell and Gene Therapy Milestones
-
Jan 22, 2026, 14:57Nirav Dhanesha on CD14 Acting As A Functional Driver of DVT
-
Jan 22, 2026, 11:41Jamilla Goedegebuur and Colleagues on VTE Management in Case of PAD
-
Jan 22, 2026, 11:28Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
-
Jan 22, 2026, 11:19Bruno Odisio: Ablation Margins Are Software-Dependent
-
Jan 22, 2026, 10:38Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase
-
Jan 22, 2026, 10:29Marvin Garcia Reyes Presents a Case of Aorto-Visceral and Aorto-Iliac Thrombosis
